Every 10-Q that Protagonist Ther (PTGX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PTGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTGX filings page.
Protagonist Therapeutics reported a sharp turnaround to profitability for the three and six months ended June 30, 2026, driven by collaboration economics. License and collaboration revenue reached $213.5 million in the quarter and $269.8 million year‑to‑date, largely from its Takeda rusfertide deal and a Janssen ICOTYDE milestone.
Net income was $162.8 million for the quarter and $166.6 million year‑to‑date, compared with losses in 2025, while cash, cash equivalents and marketable securities rose to about $849.5 million as of June 30, 2026. The Takeda opt‑out triggered a $200 million payment and positions Protagonist for royalties of 14–29% plus up to $775 million in sales milestones if rusfertide is approved and commercialized.
ICOTYDE received FDA approval in March 2026 for moderate‑to‑severe plaque psoriasis, earning a $50 million milestone and supporting future royalties of 6–10% and up to $580 million in additional milestones. Management expects research and development spending to increase significantly in the second half of 2026 as programs such as PN‑881, PN‑477, PN‑458 and PN‑8047 advance.
Protagonist Therapeutics reported a profitable first quarter of 2026 driven by collaboration milestones and a strong cash position. License and collaboration revenue reached $56.4 million, nearly doubling from the prior year period, mainly from a $50.0 million FDA-approval milestone for ICOTYDE, its oral psoriasis drug partnered with JNJ.
The company generated net income of $3.8 million, compared with a loss of $11.7 million a year earlier, as milestone revenue more than offset higher research and development spending of $46.7 million. General and administrative expenses rose to $13.3 million, reflecting headcount and stock-based compensation growth.
Cash, cash equivalents and marketable securities totaled about $620.3 million at March 31, 2026, providing substantial funding for its pipeline in inflammation, hematology and metabolic diseases. After quarter-end, Protagonist exercised its opt-out right in the Takeda rusfertide deal, triggering a $200.0 million payment and shifting the arrangement to a global royalty and milestone model.
Protagonist Therapeutics (PTGX) filed its Q3 2025 10‑Q, highlighting steady collaboration revenue and strong liquidity. License and collaboration revenue was $4.7 million for the quarter and $38.6 million year-to-date, primarily from the Takeda rusfertide agreement. The company reported a net loss of $39.3 million for Q3 and $85.8 million for the first nine months, reflecting ongoing Phase 3 development and operating costs.
Cash, cash equivalents, and marketable securities totaled $678.8 million as of September 30, 2025, supported by prior upfronts and a $25.0 million milestone from Takeda received in September 2025. Deferred revenue was $17.0 million, to be recognized as development services conclude. R&D expense was $40.0 million and G&A was $11.1 million in Q3.
Operationally, JNJ submitted an NDA to the FDA in July 2025 and an MAA to the EMA in September 2025 for icotrokinra in plaque psoriasis. Rusfertide for polycythemia vera received FDA Breakthrough Therapy designation in August 2025, with Phase 3 VERIFY positive topline results announced in March 2025. As of October 29, 2025, 62,515,666 common shares were outstanding.